Pickering John W, Joyce Laura R, Florkowski Christopher M, Buchan Vanessa, Hamill Laura, Than Martin P
Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Emergency Department, Christchurch Hospital, Private Bag 4710, Christchurch 8140, New Zealand.
Eur Heart J Acute Cardiovasc Care. 2024 Dec 24;13(12):838-842. doi: 10.1093/ehjacc/zuae114.
Point-of-care (POC) high-sensitivity troponin (hs-cTn) assays within a clinical pathway may safely reduce length of stay (LoS) for patients presenting to the emergency department (ED) with possible acute myocardial infarction (AMI). In this early report, we present the first evaluation of a POC hs-cTn in real-life care.
In adult patients presenting to ED investigated for possible AMI, we compared the LoS in patients assessed with a troponin in the 8 weeks before (usual-care phase) and the 8 weeks following introduction of the Siemens Atellica VTLi POC hs-cTnI for decision-making (intervention phase). The VTLi replaced the laboratory (Beckman Coulter) assay as the default hs-cTn test within the clinical pathway. This was the only change to the pathway process. The safety outcome was first event AMI or cardiac death within 30 days. There were 2376 presentations in the usual-care phase with 188 individuals with AMI and 2392 in the intervention phase with 198 AMI. In the intervention phase, there was a mean (95% CI) reduction in LoS of 32 min (22-41 min) compared with the usual-care phase. This represents 21.4 fewer patient-hours in the ED each day (1196 in the 8-week period). In both phases, the pathway correctly identified all cases of AMI at index attendance. There were four follow-up events (two usual-care, two intervention) within 30 days.
The deployment of a hs-cTn POC analyser into a large ED safely reduced length of stay. If translatable to other EDs, this could represent an important advancement to patient care.
Australia New Zealand Clinical Trials Registry, No. ACTRN12619001189112.
在临床路径中使用即时检验(POC)高敏肌钙蛋白(hs-cTn)检测可能会安全地缩短因可能的急性心肌梗死(AMI)而到急诊科(ED)就诊患者的住院时间(LoS)。在本早期报告中,我们展示了对POC hs-cTn在实际医疗中的首次评估。
在因可能的AMI到ED就诊的成年患者中,我们比较了在引入西门子Atellica VTLi POC hs-cTnI用于决策前8周(常规护理阶段)和引入后8周(干预阶段)使用肌钙蛋白评估患者的LoS。VTLi取代了实验室(贝克曼库尔特)检测作为临床路径中的默认hs-cTn检测。这是路径流程中唯一的改变。安全结局是30天内首次发生的AMI或心源性死亡。常规护理阶段有2376例就诊,其中188例为AMI患者;干预阶段有2392例就诊,其中198例为AMI患者。与常规护理阶段相比,干预阶段LoS平均(95%CI)缩短了32分钟(22 - 41分钟)。这意味着每天在ED的患者小时数减少了21.4小时(8周内减少了1196小时)。在两个阶段,路径在首次就诊时都正确识别了所有AMI病例。30天内有4例随访事件(2例常规护理,2例干预)。
将hs-cTn POC分析仪应用于大型ED可安全地缩短住院时间。如果能推广到其他ED,这可能代表着患者护理方面的一项重要进展。
澳大利亚新西兰临床试验注册中心,编号ACTRN12619001189112。